SCHEMBL6583641

SCHEMBL6583641

COc1ccc(-c2nc(-c3cccc(C=O)c3)nn2Cc2ccc(O)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 5/20 0.58
NR1H2 P55055 4/20 0.58
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
AKR1C3 P42330 3/20 0.44
LMNA P02545 2/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
AVPR1B P47901 2/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6581357 0.96 NR1H3 (0.53) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6578548 0.95 NR1H3 (0.64) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6581091 0.91 NR1H3 (0.71) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6581102 0.91 NR1H3 (0.57) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6578522 0.89 NR1H3 (0.59) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6582807 0.88 NR1H3 (0.66) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6581539 0.87 NR1H3 (0.64) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6582468 0.85 NR1H3 (0.53) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6580585 0.85 NR1H3 (0.56) NR1H3NR1H2NPC1RAB9ASMN1; SMN2
SCHEMBL6584155 0.84 NR1H3 (0.51) NR1H3NR1H2NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1070708-B1 Triazole derivatives HOFFMANN LA ROCHE (CH) 2004-01-14 EP disclosed
US-6265426-B1 CENTRAL NERVOUS SYSTEM DISORDERS HOFFMANN-LA ROCHE INC. 2001-07-24 US disclosed
EP-1070708-A1 Triazole and imidazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-01-24 EP disclosed